Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Fortifi-hn01: uno studio di fase 2/3 di ficerafusp alfa (BCA101) o placebo in combinazione con pembrolizumab in pd-l1-pos di prima linea, r o m hnscc (FORTIFI-HN01)

28 ottobre 2026 aggiornato da: Bicara Therapeutics

Uno studio multicentrico, randomizzato, in doppio cieco, di fase 2/3 su Ficerafusp Alfa (BCA101) o placebo in combinazione con pembrolizumab per il trattamento di prima linea del carcinoma a cellule squamose della testa e del collo PD-L1-positivo, ricorrente o metastatico

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).

This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The mechanism of action of ficerafusp alfa involves dual targeting of two cancer targets, EGFR and TGF-β, which are known to drive solid tumor growth and metastasis.

Phase 2 of the study will identify an optimal biologic dose (OBD) supported by the safety, tolerability, PK, PD, and efficacy data of ficerafusp alfa. In this part, eligible subjects will be randomized to one of three treatment arms at a 1:1:1 ratio:

  • Arm A: ficerafusp alfa 1500 mg once weekly (QW) + pembrolizumab 200 mg every three weeks (Q3W).
  • Arm B: ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W.
  • Arm C (control): placebo QW + pembrolizumab 200 mg Q3W.

The primary objective for the phase 3 portion is to compare the efficacy in subjects treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo with pembrolizumab. Eligible subjects will be randomized 2:1 in the treatment versus control arm during the phase 3 portion.

Tipo di studio

Interventistico

Iscrizione (Stimato)

650

Fase

  • Fase 2
  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Buenos Aires, Argentina, C1190
      • Buenos Aires, Argentina, C1425
        • Reclutamento
        • ICM Center (Site # 2306)
        • Contatto:
      • Pilar, Argentina, B1629ODT
        • Reclutamento
        • Hospital Universitario Austral (Site # 2303)
        • Contatto:
      • Rosario, Argentina, CP2000
        • Reclutamento
        • Sanatorio de la Mujer (Site # 2305)
        • Contatto:
      • Santa Fe, Argentina, S2002KDT
        • Reclutamento
        • Hospital Provincial del Centenario (Site # 2302)
        • Contatto:
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Reclutamento
        • Chris O'Brien Lifehouse (Site#0302)
        • Contatto:
      • Kingswood, New South Wales, Australia, 2747
        • Reclutamento
        • Nepean Hospital (Site #0306)
        • Contatto:
      • Waratah, New South Wales, Australia, 2298
        • Reclutamento
        • Calvary Mater Newcastle (Site#0304)
        • Contatto:
    • Queensland
      • Southport, Queensland, Australia, 4215
        • Reclutamento
        • Gold Coast University Hospital (Site #0305)
        • Contatto:
      • Tugun, Queensland, Australia, 4224
        • Reclutamento
        • John Flynn Private Hospital (Site#0307)
        • Contatto:
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
        • Reclutamento
        • Austin Health (Site #0303)
        • Contatto:
      • North Melbourne, Victoria, Australia, 3051
        • Reclutamento
        • Peter Macallum Cancer Centre (Site#0301)
        • Contatto:
    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • Reclutamento
        • Fiona Stanley Hospital (Site#0308)
        • Contatto:
      • Salzburg, Austria, 5020
        • Reclutamento
        • Hematology and Medical Oncology, Paracelsus Medical University (Site #1602)
        • Contatto:
      • Vienna, Austria, 1090
        • Reclutamento
        • Medical University Vienna (Site #1601)
        • Contatto:
      • Bruges, Belgio, 8000
        • Reclutamento
        • AZ St-Jan Brugge Oostende av (Campus Sint-Jan) (Site #1007)
        • Contatto:
      • Mons, Belgio, 7000
        • Reclutamento
        • CHU Ambroise Paré (Site #1005)
        • Contatto:
      • Namur, Belgio, 5000
        • Reclutamento
        • CHU UCL Namur, Site Ste. Elisabeth (Site #1002)
        • Contatto:
      • Namur, Belgio, 5530
        • Reclutamento
        • CHU UCL Namur, Site Mont-Godinne (Site #1003)
        • Contatto:
      • Sint-Niklaas, Belgio, 9100
      • Wilrijk, Belgio, 2610
        • Reclutamento
        • ZAS Augustinus (Site #1006)
        • Contatto:
      • Barretos, Brasile, 14784-400
        • Reclutamento
        • Hospital de Amor de Barretos - Fundação Pio XII (Site # 2413)
        • Contatto:
      • Belém, Brasile, 66063495
        • Reclutamento
        • Centro de Tratamento Oncologico (Site # 2421)
        • Contatto:
      • Curitiba, Brasile, 80810-050
        • Reclutamento
        • CIONC-Centro Integrado de Oncologia de Curitiba (Site # 2404)
        • Contatto:
      • Fortaleza, Brasile, 60430235
        • Reclutamento
        • Hospital Haroldo Juaçaba - Instituto do Câncer do Ceará (Site # 2414)
        • Contatto:
      • Ijuí, Brasile, 98700-000
        • Reclutamento
        • Oncosite - Centro de Pesquisa Clinica e Oncologia (Site # 2402)
        • Contatto:
      • Jaú, Brasile, 17210-120
        • Reclutamento
        • Fundação Doutor Amaral Carvalho (Site # 2411)
        • Contatto:
      • Natal, Brasile, 59062-000
        • Reclutamento
        • Liga Norte-Rio-Grandense Contra o Câncer (Site # 2422)
        • Contatto:
      • Passo Fundo, Brasile, 99010-260
        • Reclutamento
        • Hospital de Clínicas de Passo Fundo (Site # 2419)
        • Contatto:
      • Porto Alegre, Brasile, 91350-200
        • Reclutamento
        • Hospital Nossa Senhora da Conceicao (Site # 2403)
        • Contatto:
      • Rio de Janeiro, Brasile, 22250-905
        • Reclutamento
        • Grupo Oncoclínicas (Site # 2412)
        • Contatto:
      • Santa Cruz do Sul, Brasile, 96835-100
        • Reclutamento
        • Hospital Ana Nery (Site # 2415)
        • Contatto:
      • Santa Lúcia, Brasile, 30360680
        • Reclutamento
        • Oncoclinicas do Brasil Serviços Médicos S.A - Oncocentro BH (Site # 2401)
        • Contatto:
      • São Caetano do Sul, Brasile, 09541-270
        • Reclutamento
        • Centro de Oncologia do ABC - Unidade Santo Andre (Site # 2410)
        • Contatto:
      • São José do Rio Preto, Brasile, 15090-000
        • Reclutamento
        • Centro Integrado de Pesquisa do Hospital de Base de São José do Rio Preto/FUNFAR (Site # 2406)
        • Contatto:
      • São Paulo, Brasile, 01246-000
        • Reclutamento
        • Instituto do Cancer do Estado de Sao Paulo (ICESP) (Site # 2417)
        • Contatto:
      • São Paulo, Brasile, 01509-900
        • Reclutamento
        • A. C. Camargo Cancer Center (Site # 2409)
        • Contatto:
      • São Paulo, Brasile, 04014-002
        • Reclutamento
        • IBCC Núcleo de Pesquisa e Ensino (Site # 2405)
        • Contatto:
      • São Paulo, Brasile, 04543
        • Reclutamento
        • Oncoclínicas - SP (Site # 2416)
        • Contatto:
      • São Paulo, Brasile, 08270-120
        • Reclutamento
        • Hospital Santa Marcelina (Site # 2418)
        • Contatto:
    • Vitoria ES
      • Santa Cecília, Vitoria ES, Brasile, 29043-260
        • Reclutamento
        • AFECC Hospital Santa Rita de Cassia (Site # 2420)
        • Contatto:
      • Toronto, Canada, M4N 3M5
        • Reclutamento
        • Sunnybrook Health Sciences Centre (Site # 0204)
        • Contatto:
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • Reclutamento
        • BC Cancer - Vancouver (Site #0202)
        • Contatto:
    • Quebec
      • Montreal, Quebec, Canada, H2X 0C1
        • Reclutamento
        • Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame (Site #0203)
        • Contatto:
      • Hradec Králové, Cechia, 500 03
        • Reclutamento
        • Fakultni Nemocnice Hradec Kralove (FNHK) (Site # 2101)
        • Contatto:
      • Prague, Cechia, 15006
        • Reclutamento
        • Fakultni nemocnice Motol a Homolka (Site #2102)
        • Contatto:
      • Busan, Corea del Sud, 49267
        • Reclutamento
        • Kosin University Gospel Hospital (Site # 2707)
        • Contatto:
      • Goyang-si, Corea del Sud, 10408
        • Reclutamento
        • National Cancer Center (Site # 2704)
        • Contatto:
      • Hwasun, Corea del Sud, 58128
        • Reclutamento
        • Chonnam National University Hwasun Hospital (Site # 2705)
        • Contatto:
      • Seongnam, Corea del Sud, 13620
        • Reclutamento
        • Seoul National University Bundang Hospital (Site # 2706)
        • Contatto:
      • Seoul, Corea del Sud, 3080
        • Reclutamento
        • Seoul National University Hospital (Site # 2701)
        • Contatto:
      • Seoul, Corea del Sud, 3722
        • Reclutamento
        • SEVERANCE HOSPITAL, YONSEI UNIVERSITY (Site # 2702)
        • Contatto:
      • Seoul, Corea del Sud, 6351
        • Reclutamento
        • Samsung Medical Center (Site # 2703)
        • Contatto:
      • Amiens, Francia, 80480
        • Reclutamento
        • CHU Amiens - Hopital Sud (Site #0809)
        • Contatto:
      • Bordeaux, Francia, 33075
        • Reclutamento
        • CHU de Bordeaux (Site # 0812)
        • Contatto:
      • Lille, Francia, 59000
        • Reclutamento
        • Centre Oscar Lambret (Site # 0804)
        • Contatto:
      • Lyon, Francia, 69004
        • Reclutamento
        • Centre Hospitalier de la Croix Rousse (Site #0810)
        • Contatto:
      • Paris, Francia, 75005
        • Reclutamento
        • Institut Curie - site de Paris (Site # 0813)
        • Contatto:
      • Rennes, Francia, 35042
        • Reclutamento
        • CRLCC Eugene Marquis (Site #0805)
        • Contatto:
      • Saint-Grégoire, Francia, 35760
        • Reclutamento
        • Les Hopitaux Prives Rennais - Saint-Gregoire (Site #0807)
        • Contatto:
      • Strasbourg, Francia, 67200
        • Reclutamento
        • Centre Regional Lutte Contre Le Cancer - PAUL STRAUSS (Site #0808)
        • Contatto:
      • Toulouse, Francia, 31059
        • Reclutamento
        • IUCT-Oncopole (Site # 0811)
        • Contatto:
      • Vandœuvre-lès-Nancy, Francia, 54519
        • Reclutamento
        • ICL - Alexis Vautrin (Site #0806)
        • Contatto:
      • Villejuif, Francia, 94805
        • Reclutamento
        • Institut Gustave Roussy (Site #0801)
        • Contatto:
      • Aachen, Germania, 52074
        • Reclutamento
        • Universitaetsklinikum Aachen AOeR (Site #0710)
        • Contatto:
      • Berlin, Germania, 12200
        • Reclutamento
        • Charite - Campus Benjamin Franklin (Site # 0701)
        • Contatto:
      • Berlin, Germania, 12351
        • Reclutamento
        • Vivantes Klinikum Neukoelln (Site # 0714)
        • Contatto:
      • Braunschweig, Germania, 38114
        • Reclutamento
        • Staedtisches Klinikum Braunschweig gGmbH (Site # 0709)
        • Contatto:
      • Chemnitz, Germania, 09116
        • Reclutamento
        • Klinikum Chemnitz gGmbH (Site # 0705)
        • Contatto:
      • Dresden, Germania, 01067
        • Reclutamento
        • Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt (Site #0707)
        • Contatto:
      • Dresden, Germania, 01307
        • Reclutamento
        • Universitaetsklinikum Carl Gustav Carus TU Dresden (Site # 0711)
        • Contatto:
      • Düsseldorf, Germania, 40225
        • Reclutamento
        • Heinrich-Heine-Universitaet Duesseldorf (Site #0706)
        • Contatto:
      • Essen, Germania, 45147
        • Reclutamento
        • Universitaetsklinikum Essen (Site # 0716)
        • Contatto:
      • Göttingen, Germania, 37075
        • Reclutamento
        • Universitaetsmedizin Goettingen (Site # 0708)
        • Contatto:
      • Hanover, Germania, 30625
        • Reclutamento
        • Medizinische Hochschule Hannover (Site # 0718)
        • Contatto:
      • Karlsruhe, Germania, 76137
        • Reclutamento
        • Vincentius-Diakonissen-Kliniken gAG/St. Vincentius-Kliniken (Site #0717)
        • Contatto:
      • München, Germania, 81675
        • Reclutamento
        • Technische Universität München School of Medicine (Site # 0715)
        • Contatto:
      • Stuttgart, Germania, 70174
        • Reclutamento
        • Klinikum Stuttgart-Katharinenhospital (Site # 0703)
        • Contatto:
      • Ulm, Germania, 89075
        • Reclutamento
        • Universitaetsklinikum Ulm (Site # 0702)
        • Contatto:
      • Kōtoku, Giappone, 135-8550
        • Reclutamento
        • Cancer Institute Hospital of JFCR (Site # 3107)
        • Contatto:
      • Athens, Grecia, 12461
        • Reclutamento
        • U.G.H. ATTIKON - General Hospital of West Attica "H AGIA VARVARA" (Site # 1701)
        • Contatto:
      • Larissa, Grecia, 41110
        • Reclutamento
        • University General Hospital of Larissa (Site # 1702)
        • Contatto:
      • Madurai, India, 625107
        • Reclutamento
        • Meenakshi Mission Hospital & Research Centre (Site # 3003)
        • Contatto:
      • Sūrat, India, 395004
        • Reclutamento
        • Nirmal Hospital (Site # 3002)
        • Contatto:
      • Cork, Irlanda, T12 DC4A
        • Reclutamento
        • Cork University Hospital - Consultants Private Clinic (Site # 0603)
        • Contatto:
      • Dublin, Irlanda, D08 NHY1
        • Reclutamento
        • Trinity College Dublin (TCD) - St. James's Hospital (SJH) (Site #0602)
        • Contatto:
      • Dublin, Irlanda, D09 V2N0
        • Reclutamento
        • Beaumont Hospital (Site #0601)
        • Contatto:
      • Beersheba, Israele, 84101
        • Reclutamento
        • Soroka Medical Center (Site # 1901)
        • Contatto:
      • Jerusalem, Israele, 9112001
        • Reclutamento
        • Hadassah Medical Center (Site # 1903)
        • Contatto:
      • Petah Tikva, Israele, 49100
        • Reclutamento
        • Rabin Medical Center (Site # 1904)
        • Contatto:
      • Tel Aviv, Israele, 6423906
        • Reclutamento
        • Sourasky Medical Center (Site # 1902)
        • Contatto:
      • Bologna, Italia, 40138
        • Reclutamento
        • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi (Site #0904)
        • Contatto:
      • Cagliari, Italia, 09121
        • Reclutamento
        • ARNAS G. Brotzu (Site # 913)
        • Contatto:
      • Florence, Italia, 50134
        • Reclutamento
        • Azienda Ospedaliera Universitaria Careggi (Site #0911)
        • Contatto:
      • Milan, Italia, 20132
        • Reclutamento
        • Ospedale San Raffaele (Site #0907)
        • Contatto:
      • Milan, Italia, 20133
        • Reclutamento
        • Fondazione IRCCS Istituto Nazionale dei Tumori (Site #0901)
        • Contatto:
      • Milan, Italia, 20142
        • Reclutamento
        • ASST Santi Paolo e Carlo, Ospedale San Paolo Polo Universitario (Site #0905)
        • Contatto:
      • Milan, Italia, 20162
        • Reclutamento
        • Azienda Socio Sanitaria Territoriale Niguarda (Site # 0912)
        • Contatto:
      • Naples, Italia, 80131
        • Reclutamento
        • Istituto Nazionale Tumori Fondazione G. Pascale (Site #0915)
        • Contatto:
      • Naples, Italia, 80131
        • Reclutamento
        • UOC Oncoematologia AOU - University Luigi Vanvitelli (Site # 0916)
        • Contatto:
      • Padova, Italia, 35128
        • Reclutamento
        • IOV - Istituto Oncologico Veneto IRCCS (Site # 0910)
        • Contatto:
      • Palermo, Italia, 90127
        • Reclutamento
        • Policlinico P. Giaccone di Palermo (Site #0908)
        • Contatto:
      • Pavia, Italia, 27100
        • Reclutamento
        • Fondazione IRCCS Policlinico San Matteo (Site # 0903)
        • Contatto:
      • Pisa, Italia, 56126
        • Reclutamento
        • Azienda Ospedaliero Universitaria Pisana (Site # 0909)
        • Contatto:
      • Rome, Italia, 00161
        • Reclutamento
        • Azienda Ospedaliero-Universitaria Policlinico Umberto I (Site #0917)
        • Contatto:
      • Rome, Italia, 00168
        • Reclutamento
        • Fondazione Policlinico Universitario - Agostino Gemelli (Site #0918)
        • Contatto:
      • Rome, Italia, 00186
        • Reclutamento
        • Fatebenefratelli Isola Tiberina, Gemelli Isola (Site #0906)
        • Contatto:
      • Rozzano, Italia, 20089
        • Reclutamento
        • Humanitas Mirasole S.p.A (Site # 0919)
        • Contatto:
      • Siena, Italia, 53100
        • Reclutamento
        • A.O.U. Senese Policlinico Santa Maria alle Scotte (Site # 0902)
        • Contatto:
      • George Town, Malaysia, 11200
        • Reclutamento
        • Mount Miriam Cancer Hospital (Site # 2802)
        • Contatto:
      • Kuala Lumpur, Malaysia, 50586
        • Reclutamento
        • Hospital Kuala Lumpur (Site # 2803)
        • Contatto:
      • Kuala Lumpur, Malaysia, 59100
        • Reclutamento
        • University Malaya Medical centre (Site # 2805)
        • Contatto:
      • Kuching, Malaysia, 93200
        • Reclutamento
        • Sarawak General Hospital (Site # 2801)
        • Contatto:
      • Pulau Pinang, Malaysia, 10450
        • Reclutamento
        • Hospital Pulau Pinang (Site # 2804)
        • Contatto:
      • Christchurch, Nuova Zelanda, 8011
        • Reclutamento
        • Christchurch Hospital NZ (Site #0401)
        • Contatto:
      • Rotorua, Nuova Zelanda, 3010
        • Reclutamento
        • Rotorua Hospital (Site#0402)
        • Contatto:
      • Gdansk, Polonia, 80-214
        • Reclutamento
        • UNIWERSYTECKIE CENTRUM KLINICZNE (Site #1401)
        • Contatto:
      • Gliwice, Polonia, 44-102
        • Reclutamento
        • Centrum Onkologii-Instytut im.M.Sklodowskiej Curie (Site # 1405)
        • Contatto:
      • Katowice, Polonia, 40-519
        • Reclutamento
        • Pratia Onkologia Katowice (Site #1403)
        • Contatto:
      • Konin, Polonia, 62-500
        • Reclutamento
        • Przychodnia Lekarska Komed (Site #1407)
        • Contatto:
      • Krakow, Polonia, 31-826
        • Reclutamento
        • Szpital Specjalistyczny im. L.Rydygiera w Krakowie (Site #1404)
        • Contatto:
      • Siedlce, Polonia, 08-110
        • Reclutamento
        • Mazowiecki Szpital Wojewódzki im. sw. Jana Pawla II w Siedlcach Sp. z o.o. (Site #1402)
        • Contatto:
      • Warsaw, Polonia, 02-781
        • Reclutamento
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curiee - Panstwowy Instytut (Site #1406)
        • Contatto:
      • Braga, Portogallo, 4710-243
        • Reclutamento
        • Centro Clínico Académico de Braga (Site #1506)
        • Contatto:
      • Coimbra, Portogallo
        • Reclutamento
        • Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE (Site #1503)
        • Contatto:
      • Lisbon, Portogallo, 1099-023
        • Reclutamento
        • Instituto Português de Oncologia Lisboa (Site #1508)
        • Contatto:
      • Portimão, Portogallo, 8500-338
        • Reclutamento
        • Centro Hospitalar Algarve (Site #1501)
        • Contatto:
      • Porto, Portogallo, 4200-072
        • Reclutamento
        • Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (Site #1505)
        • Contatto:
      • Porto, Portogallo, 4200-319
        • Reclutamento
        • Centro Hospitalar Universitario de Sao Joao (Site #1507)
        • Contatto:
      • Senhora da Hora, Portogallo, 4464-509
        • Reclutamento
        • Unidade Local de Saude de Matosinhos, E.P.E. - Hospital Pedro Hispano (Site #1502)
        • Contatto:
      • Vila Nova de Gaia, Portogallo, 4434-502
        • Reclutamento
        • Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E. (Site # 1504)
        • Contatto:
      • Aberdeen, Regno Unito, AB25 2ZN
        • Reclutamento
        • Aberdeen Royal Infirmary (Site #0504)
        • Contatto:
      • Birmingham, Regno Unito, B15 2TH
        • Reclutamento
        • University Hospitals Birmingham (Queen Elizabeth Hospital) (Site #0512)
        • Contatto:
      • Cambridge, Regno Unito, CB2 0QQ
        • Reclutamento
        • Cambridge University Hospitals (Site #0513)
        • Contatto:
      • Glasgow, Regno Unito, G12 0YN
        • Reclutamento
        • Beatson West of Scotland Cancer Centre (Site # 0510)
        • Contatto:
      • Leeds, Regno Unito, LS9 7TF
        • Reclutamento
        • St James University Hospital Leeds (Site #0511)
        • Contatto:
      • Liverpool, Regno Unito, L7 8YA
        • Reclutamento
        • Clatterbridge Cancer Center NHS Foundation (Site #0507)
        • Contatto:
      • London, Regno Unito, SW3 6JJ
        • Reclutamento
        • Royal Marsden Hospital - Chelsea (Site #0505)
        • Contatto:
      • London, Regno Unito, WC1E 6AG
        • Reclutamento
        • University College London Hospital (Site #0502)
        • Contatto:
      • Manchester, Regno Unito, M20 4BX
        • Reclutamento
        • The Christie Hospital (Site #0508)
        • Contatto:
      • Middlesex, Regno Unito, HA6 2RN
        • Reclutamento
        • Mount Vernon Cancer Centre (Site #0506)
        • Contatto:
      • Newcastle upon Tyne, Regno Unito, NE7 7DN
        • Reclutamento
        • Newcastle University (Site # 509)
        • Contatto:
      • Nottingham, Regno Unito, NG5 1PB
        • Reclutamento
        • Nottingham University Hospitals City Campus (Site #0503)
        • Contatto:
      • Oxford, Regno Unito, OX3 7LE
        • Reclutamento
        • Churchill Hospital (Site #0515)
        • Contatto:
      • Portsmouth, Regno Unito, PO6 3LY
        • Reclutamento
        • Queen Alexandra Hospital (Site # 0514)
        • Contatto:
      • Sutton, Regno Unito, SM2 5PT
        • Reclutamento
        • Royal Marsden Hospital- London (Site # 0501)
        • Contatto:
      • Novena, Singapore, 308433
        • Reclutamento
        • Tan Tock Seng Hospital (Site # 2902)
        • Contatto:
      • Singapore, Singapore, 168583
        • Reclutamento
        • National Cancer Centre Singapore (Site # 2901)
        • Contatto:
      • Badalona, Spagna, 8916
        • Reclutamento
        • ICO Badalona - Hospital Universitari Germans Trias i Pujol (Site # 1311)
        • Contatto:
      • Barcelona, Spagna, 08035
        • Reclutamento
        • Hospital Universitari Vall d'Hebron (Site #1301)
        • Contatto:
      • Barcelona, Spagna, 08036
        • Reclutamento
        • Hospital Clinic de Barcelona (Site #1305)
        • Contatto:
      • Barcelona, Spagna, 08041
        • Reclutamento
        • Hospital de la Santa Creu I Sant Pau Site #1304
        • Contatto:
      • Barcelona, Spagna, 08908
        • Reclutamento
        • Institut Catala d'Oncologia (Site # 1302)
        • Contatto:
      • Madrid, Spagna, 28027
        • Reclutamento
        • Clinica Universidad de Navarra- Madrid (Site #1310)
        • Contatto:
      • Madrid, Spagna, 28041
        • Reclutamento
        • Hospital Universitario 12 De Octubre (Site #1303)
        • Contatto:
      • Pamplona, Spagna, 31008
        • Reclutamento
        • Clinica Universidad de Navarra (Site #1306)
        • Contatto:
      • Santander, Spagna, 39008
        • Reclutamento
        • Hospital Universitario Marques de Valdecilla (HUMV) (Site #1309)
        • Contatto:
      • Valencia, Spagna, 46010
        • Reclutamento
        • Hospital Clinico Universitario de Valencia (Site #1307)
        • Contatto:
      • Valencia, Spagna, 46014
        • Reclutamento
        • Hospital General Universitario de Valencia (Site #1308)
        • Contatto:
    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233
        • Reclutamento
        • University of Alabama Hospital (Site # 0137)
        • Contatto:
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85054
        • Reclutamento
        • Mayo Clinic Hospital (Site #0147)
        • Contatto:
    • California
      • La Jolla, California, Stati Uniti, 92093
        • Reclutamento
        • UC San Diego Moores Cancer Center (Site #0107)
        • Contatto:
      • Los Angeles, California, Stati Uniti, 90095
        • Reclutamento
        • UCLA Department of Medicine - Hematology/Oncology (Site #0106)
        • Contatto:
      • Sacramento, California, Stati Uniti, 95817
      • San Francisco, California, Stati Uniti, 94143
        • Reclutamento
        • University of California San Francisco (Site #0130)
        • Contatto:
      • Stanford, California, Stati Uniti, 94305
        • Reclutamento
        • Stanford Cancer Institute (Site #0150)
        • Contatto:
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80012
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP (Site #0122)
        • Contatto:
      • Aurora, Colorado, Stati Uniti, 80045
        • Reclutamento
        • Rocky Mountain Regional VAMC (Site #0124)
        • Contatto:
      • Aurora, Colorado, Stati Uniti, 80045
        • Reclutamento
        • University of Colorado Cancer Center (UCCC) - Anschutz Medical Campus (Site#0121)
        • Contatto:
    • Delaware
      • Newark, Delaware, Stati Uniti, 19713
        • Reclutamento
        • ChristianaCare Helen F. Graham Cancer Center and Research Institute (Site # 127)
        • Contatto:
    • Florida
      • Jacksonville, Florida, Stati Uniti, 32224
        • Reclutamento
        • Mayo Clinic Florida (Site #0148)
        • Contatto:
      • Palm Bay, Florida, Stati Uniti, 32901
        • Reclutamento
        • Cancer Care Centers of Brevard (Site #0136)
        • Contatto:
      • Tampa, Florida, Stati Uniti, 33612
        • Reclutamento
        • Moffit Cancer Center (Site #0105)
        • Contatto:
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60064
        • Reclutamento
        • Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133)
        • Contatto:
    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242
        • Reclutamento
        • University of Iowa Hospitals & Clinics (Site#0140)
        • Contatto:
    • Kansas
      • Westwood, Kansas, Stati Uniti, 66205
        • Reclutamento
        • University of Kansas Medical Center Research Institute, Inc. (Site #0149)
        • Contatto:
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40536
        • Reclutamento
        • University of Kentucky, Markey Cancer Center (Site # 109)
        • Contatto:
      • Louisville, Kentucky, Stati Uniti, 40202
        • Reclutamento
        • Norton Cancer Institute (Site#0111)
        • Contatto:
      • Louisville, Kentucky, Stati Uniti, 40202
        • Reclutamento
        • The University of Louisville, James Graham Brown Cancer Center (Site#0115)
        • Contatto:
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21201
        • Reclutamento
        • University of Maryland Medical Group (Site #0112)
        • Contatto:
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Reclutamento
        • Massachusetts General Hospital (Site #0131)
        • Contatto:
      • Boston, Massachusetts, Stati Uniti, 02136
        • Reclutamento
        • Dana-Farber Cancer Institute (Site#0101)
        • Contatto:
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48109
        • Reclutamento
        • University of Michigan (Site # 161)
        • Contatto:
    • Minnesota
      • Maplewood, Minnesota, Stati Uniti, 55109
      • Rochester, Minnesota, Stati Uniti, 55905
        • Reclutamento
        • Mayo Clinic Cancer Center - Rochester (Site #0146)
        • Contatto:
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Washington University School of Medicine (Site #0114)
        • Contatto:
    • New Jersey
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Reclutamento
        • Hackensack Meridian Health (Site # 119)
        • Contatto:
      • Newark, New Jersey, Stati Uniti, 07103
        • Reclutamento
        • Rutgers- Cancer Institute (Site #0145)
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10003
        • Reclutamento
        • Mount Sinai (Site #0155)
        • Contatto:
      • New York, New York, Stati Uniti, 10021
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center (Site#0142)
        • Contatto:
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27703
        • Reclutamento
        • Duke University Health System (Site#0118)
        • Contatto:
    • Ohio
      • Canton, Ohio, Stati Uniti, 44708
        • Reclutamento
        • Mercy Hospital (Site#0154)
        • Contatto:
      • Cincinnati, Ohio, Stati Uniti, 45221
        • Reclutamento
        • University of Cincinnati Cancer Institute (Site#0117)
        • Contatto:
      • Cleveland, Ohio, Stati Uniti, 44106
        • Reclutamento
        • University Hospitals Seidman Cancer Center (Site #0151)
        • Contatto:
      • Cleveland, Ohio, Stati Uniti, 44195
        • Reclutamento
        • Cleveland Clinic (Site #0108)
        • Contatto:
    • Oregon
      • Portland, Oregon, Stati Uniti, 97213
        • Reclutamento
        • Providence Portland Medical Center (Site #0113)
        • Contatto:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Stati Uniti, 15206
        • Reclutamento
        • UPMC Hillman Cancer Center (Site #0103)
        • Contatto:
      • Pittsburgh, Pennsylvania, Stati Uniti, 15240
        • Reclutamento
        • VA Pittsburgh Healthcare System (Site #0123)
        • Contatto:
    • Rhode Island
      • Providence, Rhode Island, Stati Uniti, 02903
        • Reclutamento
        • Lifespan Cancer Institute (Site #0132)
        • Contatto:
    • South Carolina
      • Charleston, South Carolina, Stati Uniti, 29425
        • Reclutamento
        • Medical University of South Carolina (MUSC) (Site#0104)
        • Contatto:
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • Reclutamento
        • SCRI-Oncology Partners (Site#0126)
        • Contatto:
      • Nashville, Tennessee, Stati Uniti, 37232
        • Reclutamento
        • Vanderbilt-Ingram Cancer Center (Site #0116)
        • Contatto:
    • Texas
      • Houston, Texas, Stati Uniti, 77005
        • Reclutamento
        • MD Anderson Cancer Center (Site#0102)
        • Contatto:
      • Waco, Texas, Stati Uniti, 676712
        • Reclutamento
        • SCRI- Texas Oncology- Central South (Site #0152)
        • Contatto:
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22904
        • Reclutamento
        • University of Virginia (Site#0134)
        • Contatto:
      • Richmond, Virginia, Stati Uniti, 23219
        • Reclutamento
        • Virginia Commonwealth University (VCU) Massey Cancer Center (Site #0129)
        • Contatto:
      • Richmond, Virginia, Stati Uniti, 23249
        • Reclutamento
        • Richmond Department of Veterans Affairs (Site #0138)
        • Contatto:
    • Washington
      • Edmonds, Washington, Stati Uniti, 98026
        • Reclutamento
        • Swedish Cancer Institute - North Campus Edmonds (Site # 0160)
        • Contatto:
      • Seattle, Washington, Stati Uniti, 98104
        • Reclutamento
        • Swedish Cancer Institute (Site # 0159)
        • Contatto:
      • Seattle, Washington, Stati Uniti, 98109
        • Reclutamento
        • University of Washington - Seattle Cancer Care Alliance (Site #0125)
        • Contatto:
      • Vancouver, Washington, Stati Uniti, 98684
        • Reclutamento
        • Northwest Cancer Specialists, PC (Site#0120)
        • Contatto:
    • Wisconsin
      • Madison, Wisconsin, Stati Uniti, 53705
        • Reclutamento
        • William S. Middleton Memorial Veteran's Hospital (Site #0141)
        • Contatto:
      • Madison, Wisconsin, Stati Uniti, 53792
        • Reclutamento
        • University of Wisconsin Hospital and Clinics (Site #0157)
        • Contatto:
      • Milwaukee, Wisconsin, Stati Uniti, 53233
        • Reclutamento
        • Advocate Aurora Research Institute (Site # 0153)
        • Contatto:
      • Fribourg, Svizzera, 1752
        • Reclutamento
        • HFR Fribourg Kantonsspital Fribourg (Site # 1803)
        • Contatto:
      • Geneva, Svizzera, 1205
        • Reclutamento
        • Hopitaux Universitaires de Geneve (Site # 1802)
        • Contatto:
      • Lausanne, Svizzera, 1011
        • Reclutamento
        • Centre Hospitalier Universitaire Vaudois (CHUV) (Site # 1801)
        • Contatto:
      • Bangkok, Tailandia, 10400
        • Reclutamento
        • Phramongkutklao Hospital (Site # 2505)
        • Contatto:
      • Bangkok, Tailandia, 10400
        • Reclutamento
        • Rajavithi Hospital (Site # 2504)
        • Contatto:
      • Chiang Mai, Tailandia, 50200
        • Reclutamento
        • Maharaj Nakorn Chiang Mai Hospital (Site # 2506)
        • Contatto:
      • Dusit, Tailandia, 10300
        • Reclutamento
        • Vajira Hospital (Site # 2503)
        • Contatto:
      • Hat Yai, Tailandia, 90110
        • Reclutamento
        • Songklanagarind Hospital (Site # 2502)
        • Contatto:
      • Changhua, Taiwan, 50006
        • Reclutamento
        • Changhua Christian Medical Foundation Changhua Christian Hospital (Site # 2602)
        • Contatto:
      • Kaohsiung City, Taiwan, 807
        • Reclutamento
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (Site # 2601)
        • Contatto:
      • Taichung, Taiwan, 40447
        • Reclutamento
        • China Medical University Hospital (CMUH) (Site # 2603)
        • Contatto:
      • Taipei, Taiwan, 10002
        • Reclutamento
        • National Taiwan University Hospital (Site # 2604)
        • Contatto:
      • Ankara, Turchia (Türkiye), 6100
        • Reclutamento
        • Hacettepe University Medical Faculty (Site # 1201)
        • Contatto:
      • Ankara, Turchia (Türkiye), 6520
        • Reclutamento
        • Memorial Ankara Hospital (Site # 1202)
        • Contatto:
      • Antalya, Turchia (Türkiye), 7020
        • Reclutamento
        • Memorial Antalya Hastanesi (Site # 1204)
        • Contatto:
      • Istanbul, Turchia (Türkiye), 34098
        • Reclutamento
        • Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty (Site # 1203)
        • Contatto:
      • Izmir, Turchia (Türkiye), 35330
        • Reclutamento
        • Dokuz Eylul University Medical School (Site # 1206)
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age ≥18 years on the day the Informed Consent Form is signed.
  • Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.
  • No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.
  • Archival tumor tissue or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.
  • PD-L1 CPS ≥1.
  • Measurable disease based on RECIST 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ function, as defined in the protocol.

Exclusion Criteria:

  • Disease suitable for local therapy administered with curative intent.
  • Prior treatment with anti-TGFβ therapy.
  • Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).
  • Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.
  • Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.
  • Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.
  • Life expectancy less than 3 months.
  • Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.
  • Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.
  • Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.
  • Active autoimmune disease requiring systemic treatment in the past 2 years.
  • Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.
  • Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.
  • Known history of human immunodeficiency virus (HIV).
  • Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.
  • Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.
  • Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.
  • Use of a live or live attenuated vaccine within 4 weeks prior to Screening.

Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Phase 2 Arm A

ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)

Investigational

Immunotherapy agent used in combination with investigational agent

Sperimentale: Phase 2 Arm B

ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W

Investigational

Immunotherapy agent used in combination with investigational agent

Comparatore placebo: Phase 2 Arm C

placebo QW + pembrolizumab 200 mg Q3W

Immunotherapy agent used in combination with investigational agent

Placebo Control

Sperimentale: Phase 3 OBD Arm

ficerafusp alfa OBD + pembrolizumab 200 mg Q3W

Investigational

Immunotherapy agent used in combination with investigational agent

Comparatore placebo: Phase 3 Arm C

placebo QW + pembrolizumab 200 mg Q3W

Immunotherapy agent used in combination with investigational agent

Placebo Control

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Lasso di tempo: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).

To assess safety and tolerability of ficerafusp alfa with pembrolizumab.

Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
Phase 2 - Objective Response Rate (ORR) per RECIST 1.1 by blinded independent central review (BICR)
Lasso di tempo: Approximately 1 year.

ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.

Approximately 1 year.
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Lasso di tempo: Approximately 2 years.

ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.

Approximately 2 years.
Phase 3 - Overall Survival (OS)
Lasso di tempo: Approximately 3 years.

OS: Defined as the time from the randomization to death due to any cause.

Approximately 3 years.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Phase 2 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Lasso di tempo: Approximately 1 year.

DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first, per RECIST 1.1 by BICR.

Approximately 1 year.
Phase 3 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Lasso di tempo: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).

To assess safety and tolerability of ficerafusp alfa with pembrolizumab.

Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
Phase 3 - Progression-free survival (PFS) per RECIST 1.1 by BICR.
Lasso di tempo: Approximately 3 years.

PFS: Defined as the time from randomization to the first documented PD per RECIST 1.1 as determined by BICR or death due to any cause, whichever occurs first.

Approximately 3 years.
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Lasso di tempo: Approximately 3 years.

ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS).

Approximately 3 years.
Phase 3 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Lasso di tempo: Approximately 3 years.

DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first per RECIST 1.1 by BICR.

Approximately 3 years.
Phase 3 - Clinical Benefit Rate (CBR) per RECIST 1.1 by BICR.
Lasso di tempo: Approximately 3 years.

Clinical Benefit Rate: For subject who demonstrated CR + PR + SD>6 months per RECIST 1.1 by BICR.

Approximately 3 years.
Phase 3 - ORR, per RECIST 1.1 by investigator's assessment.
Lasso di tempo: Approximately 3 years.

ORR, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - DOR, per RECIST 1.1 by investigator's assessment.
Lasso di tempo: Approximately 3 years.

DOR, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - PFS, per RECIST 1.1 by investigator's assessment.
Lasso di tempo: Approximately 3 years.

PFS, per RECIST 1.1 as determined by investigator's assessment.

Approximately 3 years.
Phase 3 - 14. Time to deterioration (TTD) in global health status measured by the EORTC QLQ C30 items for global health status and quality of life scale (item 29/30)
Lasso di tempo: Approximately 3 years.

To evaluate TTD in global health status/quality of life in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.

TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in QoL using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Item 30) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function.

Approximately 3 years.
Phase 3 - Time to deterioration (TTD) in pain measured by the EORTC HN 35 (items 31-34) pain domain.
Lasso di tempo: Approximately 3 years.

To evaluate TTD in pain in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.

TTD defined as the time from first dose (baseline) to change in pain score by 10-point from baseline, using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core Head and Neck Module (EORTC HN35). A higher score indicates a higher level of symptom burden.

Approximately 3 years.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

28 gennaio 2025

Completamento primario (Stimato)

1 aprile 2028

Completamento dello studio (Stimato)

1 luglio 2029

Date di iscrizione allo studio

Primo inviato

10 gennaio 2025

Primo inviato che soddisfa i criteri di controllo qualità

17 gennaio 2025

Primo Inserito (Effettivo)

23 gennaio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .